(Q42728646)

5 November 2017

Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis (English)

1 reference

5 November 2017

0 references

2

1 reference

5 November 2017

Michael W Konstan

1

1 reference

5 November 2017

16 November 2011

1 reference

Journal of Cystic Fibrosis

5 November 2017

1 reference

5 November 2017

11

1 reference

5 November 2017

2

1 reference

5 November 2017

78-83

1 reference

Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis.

5 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090757

Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090757

Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090757

Characterizing aggressiveness and predicting future progression of CF lung disease

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090757

Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090757

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090757

Inflammation and anti-inflammatory therapies for cystic fibrosis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090757

What's new in CF airway inflammation: an update.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090757

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090757

Estimating effectiveness in an observational study: a case study of dornase alfa in cystic fibrosis. The Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090757

Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090757

Effect of high-dose ibuprofen in patients with cystic fibrosis.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090757

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090757

Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090757

Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090757

Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090757

Release of the antimicrobial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090757

Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090757

Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090757

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090757

Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090757

Current understanding of the inflammatory process in cystic fibrosis: onset and etiology

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090757

Effect of Treatment with Dornase Alpha on Airway Inflammation in Patients with Cystic Fibrosis

16 August 2018

1 reference

12 December 2020

Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation

1 reference

12 December 2020

Early pulmonary inflammation in infants with cystic fibrosis

1 reference

12 December 2020

The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis

1 reference

12 December 2020

Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group

1 reference

12 December 2020

Identifying treatments that halt progression of pulmonary disease in cystic fibrosis

1 reference

12 December 2020

Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis

1 reference

12 December 2020

Airway inflammation after treatment with aerosolized deoxyribonuclease in cystic fibrosis

1 reference

12 December 2020

Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients

1 reference

12 December 2020

Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada

1 reference

12 December 2020

Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis

1 reference

12 December 2020

DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha

1 reference

12 December 2020

Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis

1 reference

12 December 2020

Association between practice patterns and body mass index percentile in infants and young children with cystic fibrosis

1 reference

12 December 2020

Extracellular DNA: a major proinflammatory component of Pseudomonas aeruginosa biofilms

1 reference

12 December 2020

Inhaled corticosteroids and lower lung function decline in young children with cystic fibrosis

1 reference

12 December 2020

10.1016/J.JCF.2011.10.003

Identifiers

DOI

1 reference

5 November 2017

1 reference

5 November 2017

1 reference

PMCID

4090757